Friday, 19 Jul 2019

You are here

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.

The FDA panel hearing was prompted by earlier studies that resulted in a July 2018 complete response letter for CV safety concerns. Panelists expressed concerns about the safety data, but nonetheless favored drug approval based on impressive efficacy data.  Most called for more post-marketing studies to further evaluate the long-term safety.

The FDA and sponsor presented data proving the effectiveness of romosozumab in postmenopausal osteoporosis, reducing vertebral fracture risk and trending towards a lower risk of non-vertebral fractures. 

Evenity, chemically known as romosozumab, belongs to a new class of drugs known as sclerostin inhibitors and is administered as a monthly subcutaneous injection. 

The FDA is not mandated to follow the recommendation of the panel, but generally does.

The meeting agenda, panel list and briefing documents can be found at the FDA website.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

FDA approved  romosozumab .it inhibits sclerostin .as all of us know, physiologically sclerostin inhibits WNT signaling pathway. Physiologically WNT signaling pathway leads to increased bone formation.now when we inhibit sclerostin to treat osteoporosis,inhibition of WNT signaling pathway will be removed that leads to increased bone formation and it will be worsen osteophyte formation  in osteoarthritic patients...
Osteonabolic agents most notably Romosuzumab not generally recommended as the first line for the treatment of osteoporosis, because of their substantial cost.Osteoanabolic treatment recommended in following individuals: (1) severe osteoporosis with high risk of fracture, (2) treatment failure with alternative osteoporosis agents with good adherent to treatment ( BMD loss or Fx), (3) contraindications or intolerance to other osteoporosis agents, and (4) GIOP..

More Like This

Intraarticular Capsaicin in Knee Osteoarthritis

A novel compound, synthetic trans‐capsaicin (CNTX‐4975), has been studied as an intraarticular injection and shown to significantly reduce pain in patients with chronic moderate‐to‐severe osteoarthritis of the knee. A phase II, multicenter, double‐blind study enrolled 172 knee OA patients between the ages of 45–80 years. Patients were randomized to receive either intraarticular placebo, or a high‐purity synthetic trans‐capsaicin CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg.

Increased Risk of Cardiovascular Death in Hip and Knee Osteoarthritis

Hip and knee osteoarthritis patients have been shown to have increased mortality rates from cardiovascular events when compared to the general population.

The study included patients in the Skåne Healthcare Register from southern Sweden who were 45–84 years old and seen over 2004-2014. Overall, there were 15,901 such patients in the study.

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays. A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

Mortality from Falls in the Elderly

JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age.